Ablynx believes the new funding will give the company "increased flexibility to advance programs through to clinical proof-of-concept, potentially commercialize our orphan drug program, ALX-0681, ourselves, and/or co-invest in development alongside our pharmaceutical partners," comments Edwin Moses, Ph.D., Ablynx chairman and CEO.